MiMedx Group, Inc. (MDXG)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 248 | 242 | 268 | 321 | 349 | 419 | 355 | 270 |
| Operating profit | $m | 64 | - | ||||||
| Net profit | $m | -49 | -12 | -30 | 67 | 42 | 49 | - | -11 |
| EPS reported | $ | 0.32 | 0.04 | ||||||
| Operating cashflow per share | $ | 0.50 | 0.31 | ||||||
| Capex per share | $ | 0.01 | 0.04 | ||||||
| FCF per share | $ | 0.49 | 0.27 | ||||||
| Free cash flow | $m | 73 | 41 | ||||||
| Net debt | $m | -147 | -134 | ||||||
| Book value equity | $m | 257 | 216 | ||||||
| Book value per share | $ | 1.71 | 1.46 | ||||||
| Number of shares | m | 149.72 | 147.8 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 21.16 | 116.75 | ||||||
| P/B LTM | x | 3.90 | 4.63 | ||||||
| P/S LTM | x | 2.39 | 2.82 | ||||||
| P/FCF LTM | x | 13.71 | 24.66 | ||||||
| EV/EBITDA LTM | x | 10.33 | 36.17 | ||||||
| EV/Sales LTM | x | 2.05 | 1.37 | ||||||
| Earnings Yield LTM | % | +4.73% | +0.86% | ||||||
| FCF Yield | % | +7.29% | +4.06% | ||||||
| Quality | |||||||||
| ROE | % | +18.94% | +2.61% | ||||||
| ROIC | % | +16.66% | +1.94% | ||||||
| Operating margin | % | +15.26% | +2.46% | ||||||
| Gross margin | % | +82.56% | +78.85% | ||||||
| FCF/Sales | % | +17.43% | +11.42% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +14.29% | - | ||||||
| Sales Growth YoY | % | +19.99% | +1.80% | ||||||
| Net Income Growth YoY | % | +14.52% | - | ||||||
| FCF Growth | % | +13.11% | -37.11% | ||||||
| Operating Profit Growth | % | +8.53% | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 3.24 | 27.05 | ||||||
| Net Debt/EBITDA | x | -1.73 | -5.67 | ||||||
| EBIT/Net interest | x | 35.83 | 5.50 | ||||||
| Net debt/market cap | % | +1.93% | +0.24% | ||||||
| Net debt/Equity | x | -0.57 | -0.62 | ||||||
| Gross debt/equity | x | 0.09 | 0.01 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free